Subrata Das
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Subrata Das has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Anupam Das Talukdar
Assam University
1 shared publication- Anupam Das Talukdar
Department of Life Science and Bioinformatics, Assam University, Silchar, 788011, India
1 shared publication Deepa Nath
Gurucharan College
1 shared publicationDipika Das
District Institute of Education and Training
1 shared publication- Gitishree Das
Department of Food Science and Biotechnology, College of Life Science and Biotechnology, Dongguk University-Seoul, Goyang-si 10326, Republic of Korea
1 shared publication - Jayanta Kumar Patra
Research Institute of Integrative Life Sciences, Dongguk University-Seoul, Goyangsi, 10326, Republic of Korea
1 shared publication
Latest Publications
- 11 December 2024
- Published by Springer Nature
- p. 493-505
CRISPR/Cas9 System of Crop Improvement: Understanding the Underlying Machinery
- 11 December 2024
- Published by Springer Nature
- p. 493-505
CRISPR/Cas9 System of Crop Improvement: Understanding the Underlying Machinery
- Open Access
Anti-Cancer Agent: The Labdane Diterpenoid-Andrographolide
In spite of the progress in treatment strategies, cancer remains a major cause of death worldwide. Therefore, the main challenge should be the early diagnosis of cancer and the design of an optimal therapeutic strategy to increase the patient’s life expectancy as well as the continuation of the search for increasingly active and selective molecules for the treatment of different forms of cancer. In the recent decades, research in the field of natural compounds has increasingly shifted towards advanced and molecular level understandings, thus leading to the development of potent anti-cancer agents. Among them is the diterpene lactone andrographolide, isolated from Andrographis paniculata (Burm.f.) Wall. ex Nees that showed shows a plethora of biological activities, including not only anti-cancer activity, but also anti-inflammatory, anti-viral, anti-bacterial, neuroprotective, hepatoprotective, hypoglycemic, and immunomodulatory properties. Andrographolide has been shown to act as an anti-tumor drug by affecting specific molecular targets that play a part in the development and progression of several cancer types including breast, lung, colon, renal, and cervical cancer, as well as leukemia and hepatocarcinoma. This review comprehensively and systematically summarized the current research on the potential anti-cancer properties of andrographolide highlighting its mechanisms of action, pharmacokinetics, and potential side effects and discussing the future perspectives, challenges, and limitations of use.
Open AccessAnti-Cancer Agent: The Labdane Diterpenoid-Andrographolide
In spite of the progress in treatment strategies, cancer remains a major cause of death worldwide. Therefore, the main challenge should be the early diagnosis of cancer and the design of an optimal therapeutic strategy to increase the patient’s life expectancy as well as the continuation of the search for increasingly active and selective molecules for the treatment of different forms of cancer. In the recent decades, research in the field of natural compounds has increasingly shifted towards advanced and molecular level understandings, thus leading to the development of potent anti-cancer agents. Among them is the diterpene lactone andrographolide, isolated from Andrographis paniculata (Burm.f.) Wall. ex Nees that showed shows a plethora of biological activities, including not only anti-cancer activity, but also anti-inflammatory, anti-viral, anti-bacterial, neuroprotective, hepatoprotective, hypoglycemic, and immunomodulatory properties. Andrographolide has been shown to act as an anti-tumor drug by affecting specific molecular targets that play a part in the development and progression of several cancer types including breast, lung, colon, renal, and cervical cancer, as well as leukemia and hepatocarcinoma. This review comprehensively and systematically summarized the current research on the potential anti-cancer properties of andrographolide highlighting its mechanisms of action, pharmacokinetics, and potential side effects and discussing the future perspectives, challenges, and limitations of use.